Indazole-Based Potent and Cell-Active Mps1 Kinase Inhibitors: Rational Design from Pan-Kinase Inhibitor Anthrapyrazolone (SP600125)

详细信息    查看全文

• 作者：Ken-ichi Kusakabe ; Nobuyuki Ide ; Yataro Daigo ; Yuki Tachibana ; Takeshi ; Itoh ; Takahiko Yamamoto ; Hiroshi Hashizume ; Yoshio Hato ; Kenichi Higashino ; Yousuke Okano ; Yuji Sato ; Makiko Inoue ; Motofumi Iguchi ; Takayuki Kanazawa ; Yukichi Ishioka ; Keiji Dohi ; Yasuto Kido ; Shingo Sakamoto ; Kazuya Yasuo ; Masahiro Maeda ; Masayo Higaki ; Kazuo Ueda ; Hidenori Yoshizawa ; Yoshiyasu Baba ; Takeshi Shiota ; Hitoshi Murai ; Yusuke Nakamura
• 刊名：Journal of Medicinal Chemistry
• 出版年：2013
• 出版时间：June 13, 2013
• 年：2013
• 卷：56
• 期：11
• 页码：4343-4356
• 全文大小：606K
• 年卷期：v.56,no.11(June 13, 2013)
• ISSN：1520-4804

文摘

Monopolar spindle 1 (Mps1) is essential for centrosome duplication, the spindle assembly check point, and the maintenance of chromosomal instability. Mps1 is highly expressed in cancer cells, and its expression levels correlate with the histological grades of cancers. Thus, selective Mps1 inhibitors offer an attractive opportunity for the development of novel cancer therapies. To design novel Mps1 inhibitors, we utilized the pan-kinase inhibitor anthrapyrazolone (4, SP600125) and its crystal structure bound to JNK1. Our design efforts led to the identification of indazole-based lead 6 with an Mps1 IC₅₀ value of 498 nM. Optimization of the 3- and 6-positions on the indazole core of 6 resulted in 23c with improved Mps1 activity (IC₅₀ = 3.06 nM). Finally, application of structure-based design using the X-ray structure of 23d bound to Mps1 culminated in the discovery of 32a and 32b with improved potency for cellular Mps1 and A549 lung cancer cells. Moreover, 32a and 32b exhibited reasonable selectivities over 120 and 166 kinases, respectively.